Compare Gilead Sciences, Inc. (GILD) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs TORM plc — how do they compare? Gilead Sciences, Inc. trades at $134.6 (market cap $163.51B), while TORM plc trades at $29.81 (market cap $2.97B). The key difference: Gilead Sciences, Inc. is far larger — about 55.1× TORM plc's market cap, and TORM plc pays the higher dividend (9.45%). Which is the better fit depends on your goals.
| GILD | TRMD | |
|---|---|---|
Market Cap | $163.51B | $2.97B |
Sector | Health | Technology |
52-Week High | $155.80 | $34.87 |
52-Week Low | $108.22 | $17.50 |
Enterprise Value | $178.05B | $3.86B |
Dividend Yield | 2.49% | 9.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
TRMD trades at $29.77, up 1.17% today, with strong technical momentum showing bullish moving averages and support at $29. The company demonstrates robust fundamentals with a P/E of 8.69, net margin of 24.41%, and consistent dividend payments including the upcoming $0.70 distribution. Recent earnings showed mixed results with a Q4 beat but Q1 miss against expectations.
TRMD presents a compelling value opportunity with attractive valuation metrics and strong profitability, though near-term volatility and earnings consistency remain key considerations. The unanimous analyst buy rating and bullish technical setup support upside potential, while investors should monitor execution on Q2 expectations and tanker market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
